Skip to content
DataLookout
Menu

SUPLANCT06507059

Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals

StatusActive, Not Recruiting
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 13 words Show 8 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Enrollment closed, study ongoing
    • Primary completion date changed from estimate of Jul 1, 2025 to Aug 6, 2025
    • Study completion pushed from Dec 31, 2026 to Feb 28, 2027
    • Interventions: Antiretroviral Combinations (Drug), cabotegravir/rilpivirine (600mg/ 900mg) (Drug) to Antiretroviral Combinations (Drug), cabotegravir/rilpivirine (600mg/ 900mg) (Drug)
    • Secondary endpoints: details revised at 4 of 13 entries
    • Study description revised
    • Site details revised at 4 of 4 sites
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 10, 2024 to Jul 19, 2024
    • Site details revised at 4 of 4 sites
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

HIV-1 RNA <200 copies/mL
Timeframe: Week 24

Secondary (13)

HIV-1 RNA <50 copies/mL
HIV-1 RNA <200 copies/mL
Change of plasma HIV-1 viral load
Change of CD4 count
Occurrence of HIV and non-HIV related conditions
Show 8 moreShow less
Lost F/U rate
Usage of outreach drug delivery service
Resistant variant emergence
Adverse events
Discontinuation due to AEs
Change of depression score
Change of self-stigma score
Change of metabolic parameters

Arms and interventions

Immediate Long-Acting Injectable Treatment GroupExperimental

Immediate switch to long-acting injectable antiretrovirals on enrollment

Delayed Long-Acting Injectable Treatment GroupActive comparator

Keep on standard all-oral antiretrovirals on enrollment for 24 weeks, then switch to long-acting injectable antiretrovirals

Drugs: cabotegravir/rilpivirine (600mg/ 900mg), Antiretroviral Combinations

Sites

4 sites in 1 country